Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.

Takuya ShoGoki SudaKoji OgawaTaku ShigesawaKazuharu SuzukiAkihisa NakamuraMasatsugu OharaMachiko UmemuraNaoki KawagishiMitsuteru NatsuizakaMasato NakaiKenichi MorikawaKen FuruyaMasaru BabaJun ItoYoshiya YamamotoTomoe KobayashiTakashi MeguroAkiyoshi SagaTakuto MiyagishimaKatsumi TerasitaTomofumi TakagiToshiya KamiyamaAkinobu TaketomiNaoya Sakamoto

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)

Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria. However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion.

Keyphrases

study protocol
tyrosine kinase
phase iii
cell migration
randomized controlled trial
radiation therapy
combination therapy
epidermal growth factor receptor
smoking cessation